An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

Item

http://www.wikidata.org/entity/Q34048630

Q34048630

about

Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy.Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer Androgen deprivation therapy for prostate cancer-review of indications in 2010 Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.Contemporary role of androgen deprivation therapy for prostate cancer The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control.Hormone therapy in the management of prostate cancer: evidence-based approaches Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer.HDR Brachytherapy in the Management of High-Risk Prostate Cancer.Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer.Tissue biomarkers for prostate cancer radiation therapy.Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy.Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.Analysis of Geometric Shifts and Proper Setup-Margin in Prostate Cancer Patients Treated With Pelvic Intensity-Modulated Radiotherapy Using Endorectal Ballooning and Daily Enema for Prostate Immobilization A prospective comparison of acute intestinal toxicity following whole pelvic versus small field intensity-modulated radiotherapy for prostate cancer.Comparison study of intensity modulated arc therapy using single or multiple arcs to intensity modulated radiation therapy for high-risk prostate cancer.Use of androgen deprivation therapy in prostate cancer: indications and prevalence.The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005.Radiotherapy and Hormone Treatment in Prostate Cancer The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT).Radiation therapy approaches to the treatment of high-risk prostate cancer.Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer.Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report.Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

P2860

Q26744606-5412DBF9-3D72-4FBB-8CEF-176F8229E0C4 Q28218423-34DFE10A-01DD-47EC-BC37-E7BAA890E299 Q31028126-C311D646-12FF-43C5-9B03-5316146E599B Q31083823-04ADAE7B-4CC2-4D2D-B571-6FBAD63C9536 Q33583944-F2F7CC85-E3C1-449E-BA6C-640244B3294D Q33765122-050DCE9B-9E28-4905-8DAE-B1319E151533 Q34104391-3848AE2E-59A2-4D4C-A40F-B77F0486EC62 Q34111603-9349F3F2-7236-4922-AB19-FA428474E0B6 Q34187079-9E4B2E27-7042-425B-A13E-DA61789012E9 Q34211155-901F5D6A-30B9-4E57-B2E3-85F1668BC28D Q34433023-3E2AB774-49C6-46B7-BB5D-D361CCD15929 Q34611812-042BFD6B-BFA5-4572-B6C1-293FE607CA85 Q34810730-DAC62E93-2F2B-4A25-98D9-0D04205BA6EC Q34996654-2DC39CAE-7FDC-42BE-A12A-300F96F6C040 Q34998545-538FC9F0-1949-4978-8780-A1E4C4AE39E0 Q35076432-35B8D5DE-5311-4A22-B70E-452C8DFAB0F6 Q35771166-5DE6EDFD-E10A-4BC0-B8F9-CE0F21EE1D56 Q35803832-BADC4288-8C7B-49F3-945F-ACB4A605D359 Q35810413-295ED245-C1F1-4AAA-A5DF-BD20A8760250 Q35835108-366F07CE-A874-40AB-B4BC-31B52D38B051 Q35947920-395BA4F5-951B-480E-B391-0BA6B7690A30 Q36141341-7F8E2567-3CD6-4766-A14B-4FAAE6A45B6C Q36293177-F172A6E7-EFFF-473A-9AD1-8386D96F7C9E Q36360358-0B8FCF3D-78F6-43C6-B4EB-3A6B294A81FB Q36474222-F75FA6ED-12A7-4881-98AB-55BFC683236D Q36478072-E4163DEF-8F02-48C4-BEF2-E266DD6B9534 Q36684017-2680DB00-8694-4474-837C-D8395F6E0FFE Q37015346-6436ED2D-CE2A-4BCE-A8A0-35B5B588D901 Q37074379-83711592-90F6-47DC-AE2B-FB30FC172411 Q37154093-B58AC224-0144-4D34-8DEB-4EF4DFFAE44D Q37158281-B22518E4-0591-469F-97BF-04FCB0DF6344 Q37176612-498D9B7A-333F-45D4-A1F5-C4EDC59327DF Q37195789-7214C0E6-27AD-48B8-A14B-19338D58945D Q37214143-C5EEC027-6A89-4468-8527-AA60743325AF Q37396108-4AD414DA-F85A-49C7-95E9-B2815EC779AF Q37401422-FBDD08E6-544B-45C1-90ED-A2F3F90A3E52 Q37446029-535D8671-9D4D-4BBA-B529-5CB7ACC0B83B Q37460247-ED5454DF-F387-4B4A-8D07-BB3ED01A65FA Q37549491-49EEAEC3-233F-4192-89FF-B6A74FDAB3AE Q37563875-B9B60410-B28C-45BA-A194-8E2B80A204BC

P2860

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

Item

http://www.wikidata.org/entity/Q34048630

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu